Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose to explore the hypothesis-supported by limited data-that a
contraceptive vaginal ring (CVR) that is commonly used in the United States, the NuvaRing,
will enhance women's genital and reproductive health. The investigators propose that this CVR
will increase the bacteria that help the vaginal environment protect against infection by HIV
and other STIs, and that in women who already have HIV, use of the CVR will lower the
quantity of HIV that is shed in the female genital tract.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)